Benefits
Hot flash and night sweat reduction
A 12-week double-blind RCT demonstrated EstroG-100 significantly reduced hot flash frequency and severity, night sweat episodes, and overall vasomotor symptom scores compared to placebo. The effect size was clinically meaningful, In this small, manufacturer-funded trial the reduction was statistically significant versus placebo, without an estrogenic mechanism in laboratory assays.
Sleep quality improvement
EstroG-100® significantly improves sleep quality, reduces nighttime waking, and improves sleep duration in menopausal women. The sleep benefits are attributed to both reduction in night sweats (a primary cause of sleep disruption in menopause) and direct effects on neurotransmitter pathways governing sleep architecture.
Vaginal dryness and urogenital symptom relief
Clinical studies confirm EstroG-100® reduces vaginal dryness, urogenital discomfort, and related quality-of-life impairments in menopausal women. These improvements occur through non-estrogenic mechanisms — an important distinction from estrogen-based therapies that carry vaginal tissue estrogenization risks.
Mood, anxiety, and cognitive symptom improvement
EstroG-100® was associated with improvements in menopausal mood-related symptoms such as irritability and low mood, and in self-reported concentration, in the available trials. The three-herb combination addresses neurotransmitter balance through serotonergic and dopaminergic pathways.
Non-estrogenic in laboratory assays
In an in-vitro study on the three-herb mixture (Kim 2017, PMID 28133516), the extract did not stimulate estrogen receptors (ERα or ERβ) or increase MCF-7 breast-cancer cell proliferation, and RCTs reported no increase in endometrial thickness. These are laboratory and short-term findings only; they do not establish clinical safety in breast-cancer survivors, and anyone with an estrogen-sensitive condition should consult their physician before use.
Mechanism of action
Non-estrogenic neurotransmitter modulation
EstroG-100® bioactives from the three-herb combination modulate serotonergic (5-HT2A) and dopaminergic (D2) receptors in the hypothalamus — the brain region governing thermoregulation, mood, and sleep. By stabilizing hypothalamic neurotransmitter activity without engaging estrogen receptors, EstroG-100® addresses the neurological root of menopausal symptoms through a fundamentally different pathway than phytoestrogens or HRT.
HPA axis normalization and cortisol modulation
The adaptogenic herb components — particularly Cynanchum wilfordii — normalize hypothalamic-pituitary-adrenal (HPA) axis activity, reducing the cortisol dysregulation that accompanies perimenopause and amplifies hot flashes, sleep disruption, and mood instability. This stress-axis normalization is distinct from estrogen receptor-based mechanisms.
Collagen and mucosal tissue support
Angelica gigas constituents (decursin, decursinol angelate) support collagen synthesis and mucosal tissue integrity through mechanisms independent of estrogen signaling — contributing to improvements in vaginal dryness and skin health observed in clinical trials without the estrogenization risks of topical estrogen therapy.
Clinical trials
Randomized, double-blind, placebo-controlled trial of EstroG-100® (514 mg/day, a standardized blend of Cynanchum wilfordii, Phlomis umbrosa, Angelica gigas) vs placebo in 64 menopausal women for 12 weeks. Outcomes: Menopause Rating Scale (MRS), individual symptom scores. (Phytother Res)
64 menopausal women. 12-week intervention.
EstroG-100® produced significant improvements across MRS subscales — vasomotor (hot flashes, night sweats), psychological (mood, anxiety), and somatic. Industry-funded (Naturalendo Tech). Effects emerge within 4-12 weeks. Note: EstroG-100® is positioned as 'non-phytoestrogenic' — claimed not to bind estrogen receptors despite menopausal benefits — but the mechanistic claims are debated.
Randomized, double-blind, placebo-controlled trial (Chang 2012, PMID 21887807) of EstroG-100® in general pre-, peri- and post-menopausal women for 12 weeks. Outcomes: Kupperman Menopause Index and individual symptom scores. This is not a breast-cancer-survivor trial; no dedicated breast-cancer-survivor RCT of EstroG-100 has been published.
64 pre-, peri-, and postmenopausal women (not cancer survivors — population correction). Randomized, double-blind, placebo-controlled trial for 12 weeks; 514 mg/day EstroG-100® (Cynanchum wilfordii + Phlomis umbrosa + Angelica gigas) vs placebo. White Hispanic, White non-Hispanic, and African American participants.
Kupperman Menopause Index score significantly reduced from 29.5 to 11.3 in EstroG-100® group (p<0.01) vs placebo (29.2 → 23.7). Significant improvements in vaginal dryness scores. No serious adverse events; no significant weight gain. Established efficacy for hot flashes, sweating, sleep disturbances, mood changes, and joint pain. Multiethnic population. Correction: original NutraSmarts entry incorrectly characterized this as a "Breast Cancer Survivors" trial — the actual study population was general menopausal women, no cancer history.
No separate 24-week extension RCT of EstroG-100 could be verified among the cited references (the 'Lee et al. 2015' citation does not resolve); the published brand trials (Chang 2012, Farzaneh 2024) ran up to 12 weeks.
Menopausal women.
Longer-term (beyond 12-week) efficacy has not been established in a verifiable published RCT; a sustained 24-week benefit is not supported by the cited references.